Akèy › Kansè vejik › Texas › Dallas
Etid klinik pou Kansè vejik nan Dallas, TX
27 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Ap rekriteFaz 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Ap rekriteFaz 1
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- ak 2 plis
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- Urology Clinics of North Texas, PLLC, Dallas
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Ap rekriteFaz 2/3
- Research Site, Dallas
Measuring Surgical Recovery After Radical Cystectomy
Ap rekriteEtid obsèvasyon
- University of Texas - Southwestern, Dallas
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Ap rekriteFaz 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- Baylor Scott & White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Ap rekriteFaz 3
- Research Site, Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- Baylor Scott and White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Ap rekriteFaz 1
- NEXT Dallas, Dallas
Predicting BCG Response
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Ap rekrite
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
Ap rekrite
- University of Texas Southwestern Medical Center, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology - Dallas, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center at Dallas, Dallas
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- UT Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Dallas
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Washington, DC26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Philadelphia, PA21 etid
- Seattle, WA21 etid
- Edison, NJ21 etid
- Chicago, IL21 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
- Maladi kadyovaskilè23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.